Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years * Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL) * In neo-adjuvant, adjuvant, recurrence or metastatic situation * Suffering from solid tumor histologically documented * Signed written informed consent * Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion. Exclusion Criteria: * Pregnant or breastfeeding women * Patient already treated by immunotherapy by immune checkpoint inhibitor * Person under guardianship * Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)